{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T13:12:32Z","timestamp":1792156352611,"version":"4.4.0"},"reference-count":29,"publisher":"Oxford University Press (OUP)","issue":"6","license":[{"start":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T00:00:00Z","timestamp":1580256000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"name":"UCB Pharma and Shire"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,6,15]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Study Objectives<\/jats:title>\n                  <jats:p>To define clinically relevant Narcolepsy Severity Scale (NSS) score ranges, confirm its main performances and sensitivity to medications, and determine whether items need to be weighted.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>One hundred and forty-three consecutive untreated and 238 treated adults with narcolepsy type 1 (NT1) completed the NSS, a 15-item self-administered questionnaire (score: 0\u201357) that assesses the severity and consequences of the five major narcolepsy symptoms such as daytime sleepiness, cataplexy, hallucinations, sleep paralysis, and disturbed nighttime sleep (DNS). They also completed the Epworth Sleepiness scale (ESS; daytime sleepiness), Beck Depression Inventory (BDI; depressive symptoms), and EQ5D (quality of life).<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>The mean symptom number (4.3 vs 3.5), NSS total score (33.3 \u00b1 9.4 vs 24.3 \u00b1 10.2), and number of narcolepsy symptoms (five symptoms: 53.1% vs 24.8%; four symptoms: 26.6% vs 22.7%; three symptoms: 15.4% vs 32.4%; two symptoms: 4.9% vs 20.2%) were significantly different between untreated and treated patients (p &amp;lt; 0.0001). DNS was often the third symptom (95.5 per cent). The symptom number was associated with diagnosis delay, age at onset, and ESS and BDI scores. Comparisons with ESS, BDI and EQ5D showed that NSS item weighting was not necessary to highlight between-group differences. Four NSS severity levels were defined (mild, moderate, severe, and very severe) with between-group differences related to treatment. The probability of having ESS \u2265 16, BDI \u2265 20, and EQ-5D &amp;lt; 60 increased with the severity level.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>NSS is valid, reliable, and responsive to treatment in patients with NT1, with four clinically relevant severity score ranges provided. NSS has adequate clinimetric properties for broadening its use for both clinic and research.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/sleep\/zsaa009","type":"journal-article","created":{"date-parts":[[2020,1,29]],"date-time":"2020-01-29T06:47:26Z","timestamp":1580280446000},"source":"Crossref","is-referenced-by-count":68,"title":["Narcolepsy Severity Scale: a reliable tool assessing symptom severity and consequences"],"prefix":"10.1093","volume":"43","author":[{"given":"Yves","family":"Dauvilliers","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"},{"name":"INSERM 1061, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucie","family":"Barateau","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"},{"name":"INSERM 1061, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis","family":"Lopez","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"},{"name":"INSERM 1061, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna Laura","family":"Rassu","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofiene","family":"Chenini","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Beziat","sequence":"first","affiliation":[{"name":"National Reference Network for Narcolepsy, Sleep-Wake Disorders Unit, Department of Neurology, Gui-de-Chauliac Hospital, CHU Montpellier, University of Montpellier, Montpellier, France"},{"name":"INSERM 1061, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8205-7590","authenticated-orcid":false,"given":"Isabelle","family":"Jaussent","sequence":"first","affiliation":[{"name":"INSERM 1061, Neuropsychiatry: Epidemiological and Clinical Research, University of Montpellier, Montpellier, France"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,1,29]]},"reference":[{"issue":"9560","key":"2020061504534200800_CIT0001","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0140-6736(07)60237-2","article-title":"Narcolepsy with cataplexy","volume":"369","author":"Dauvilliers","year":"2007","journal-title":"Lancet."},{"issue":"27","key":"2020061504534200800_CIT0002","doi-asserted-by":"crossref","first-page":"2654","DOI":"10.1056\/NEJMra1500587","article-title":"Narcolepsy","volume":"373","author":"Scammell","year":"2015","journal-title":"N Engl J Med."},{"issue":"7","key":"2020061504534200800_CIT0003","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/nrneurol.2014.97","article-title":"Cataplexy\u2013clinical aspects, pathophysiology and management strategy","volume":"10","author":"Dauvilliers","year":"2014","journal-title":"Nat Rev Neurol."},{"issue":"9","key":"2020061504534200800_CIT0004","doi-asserted-by":"crossref","first-page":"955","DOI":"10.5664\/jcsm.3004","article-title":"Disrupted nighttime sleep in narcolepsy","volume":"9","author":"Roth","year":"2013","journal-title":"J Clin Sleep Med."},{"issue":"9","key":"2020061504534200800_CIT0005","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1038\/s41582-019-0226-9","article-title":"Narcolepsy \u2013 clinical spectrum, aetiopathophysiology, diagnosis and treatment","volume":"15","author":"Bassetti","year":"2019","journal-title":"Nat Rev Neurol."},{"issue":"5","key":"2020061504534200800_CIT0006","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1111\/jsr.12044","article-title":"Clinical, polysomnographic and genome-wide association analyses of narcolepsy with cataplexy: a European Narcolepsy Network study","volume":"22","author":"Luca","year":"2013","journal-title":"J Sleep Res."},{"issue":"14","key":"2020061504534200800_CIT0007","doi-asserted-by":"crossref","first-page":"1358","DOI":"10.1212\/WNL.0000000000003787","article-title":"Measurement of narcolepsy symptoms: the Narcolepsy Severity Scale","volume":"88","author":"Dauvilliers","year":"2017","journal-title":"Neurology."},{"issue":"5","key":"2020061504534200800_CIT0008","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.sleep.2014.02.001","article-title":"The Burden of Narcolepsy Disease (BOND) study: health-care utilization and cost findings","volume":"15","author":"Black","year":"2014","journal-title":"Sleep Med."},{"issue":"1","key":"2020061504534200800_CIT0009","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1046\/j.1365-2869.2001.00234.x","article-title":"Health-related quality of life in narcolepsy","volume":"10","author":"Daniels","year":"2001","journal-title":"J Sleep Res."},{"issue":"6","key":"2020061504534200800_CIT0010","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1136\/jnnp.2008.161588","article-title":"Psychological health in central hypersomnias: the French Harmony study","volume":"80","author":"Dauvilliers","year":"2009","journal-title":"J Neurol Neurosurg Psychiatry."},{"issue":"6","key":"2020061504534200800_CIT0011","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1016\/j.sleep.2013.03.002","article-title":"Narcolepsy is complicated by high medical and psychiatric comorbidities: a comparison with the general population","volume":"14","author":"Ohayon","year":"2013","journal-title":"Sleep Med."},{"key":"2020061504534200800_CIT0012","volume-title":"International classification of sleep disorders-third edition (ICSD-3)","author":"American Academy of Sleep Medicine.","year":"2014"},{"key":"2020061504534200800_CIT0013","volume-title":"Manual for the Beck Depression Inventory-II","author":"Beck","year":"1996"},{"issue":"6","key":"2020061504534200800_CIT0014","doi-asserted-by":"crossref","first-page":"540","DOI":"10.1093\/sleep\/14.6.540","article-title":"A new method for measuring daytime sleepiness: the Epworth sleepiness scale","volume":"14","author":"Johns","year":"1991","journal-title":"Sleep."},{"issue":"4","key":"2020061504534200800_CIT0015","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/S1389-9457(00)00065-4","article-title":"Validation of the Insomnia Severity Index as an outcome measure for insomnia research","volume":"2","author":"Bastien","year":"2001","journal-title":"Sleep Med."},{"key":"2020061504534200800_CIT0016","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","article-title":"EuroQol--a new facility for the measurement of health-related quality of life","volume":"16","author":"EuroQol Group","year":"1990","journal-title":"Health Policy"},{"issue":"9","key":"2020061504534200800_CIT0017","doi-asserted-by":"crossref","first-page":"2137","DOI":"10.1007\/s00415-019-09365-2","article-title":"The Swiss Narcolepsy Scale (SNS) and its short form (sSNS) for the discrimination of narcolepsy in patients with hypersomnolence: a cohort study based on the Bern Sleep-Wake Database","volume":"266","author":"Bargiotas","year":"2019","journal-title":"J Neurol."},{"key":"2020061504534200800_CIT0018","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1111\/j.1365-2869.1994.tb00104.x","article-title":"The Ullanlinna Narcolepsy Scale: validation of a measure of symptoms in the narcoleptic syndrome","volume":"3","author":"Hublin","year":"1994","journal-title":"J Sleep Res"},{"key":"2020061504534200800_CIT0019","doi-asserted-by":"crossref","DOI":"10.1093\/sleep\/zsy238","article-title":"Ullanlinna Narcolepsy Scale in diagnosis of narcolepsy","volume":"42","author":"Sarkanen","year":"2019","journal-title":"Sleep"},{"key":"2020061504534200800_CIT0020","doi-asserted-by":"crossref","DOI":"10.1177\/2514183X18794175","article-title":"Swiss Narcolepsy Scale: A simple screening tool for hypocretin-deficient narcolepsy with cataplexy","author":"Sturzenegger","year":"2018;2(2)","journal-title":"Clin Transl Neurosci"},{"issue":"7","key":"2020061504534200800_CIT0021","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1093\/sleep\/29.7.939","article-title":"Sodium oxybate improves excessive daytime sleepiness in narcolepsy","volume":"29","author":"Black","year":"2006","journal-title":"Sleep."},{"issue":"11","key":"2020061504534200800_CIT0022","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.1016\/S1474-4422(13)70225-4","article-title":"Pitolisant versus placebo or modafinil in patients with narcolepsy: a double-blind, randomised trial","volume":"12","author":"Dauvilliers","year":"2013","journal-title":"Lancet Neurol."},{"key":"2020061504534200800_CIT0023","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1002\/ana.410430115","article-title":"Randomized trial of modafinil for the treatment of pathological somnolence in narcolepsy. US Modafinil in Narcolepsy Multicenter Study Group","volume":"43","year":"1998","journal-title":"Ann Neurol"},{"issue":"8","key":"2020061504534200800_CIT0024","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/j.sleep.2012.06.006","article-title":"Health, social, and economic consequences of narcolepsy: a controlled national study evaluating the societal effect on patients and their partners","volume":"13","author":"Jennum","year":"2012","journal-title":"Sleep Med."},{"key":"2020061504534200800_CIT0025","doi-asserted-by":"crossref","first-page":"16100","DOI":"10.1038\/nrdp.2016.100","article-title":"Narcolepsy","volume":"3","author":"Kornum","year":"2017","journal-title":"Nat Rev Dis Primers."},{"issue":"1","key":"2020061504534200800_CIT0026","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/s41572-018-0016-5","article-title":"REM sleep behaviour disorder","volume":"4","author":"Dauvilliers","year":"2018","journal-title":"Nat Rev Dis Primers."},{"issue":"5","key":"2020061504534200800_CIT0027","doi-asserted-by":"crossref","first-page":"737","DOI":"10.5664\/jcsm.6596","article-title":"Patient-reported measures of narcolepsy: the need for better assessment","volume":"13","author":"Kallweit","year":"2017","journal-title":"J Clin Sleep Med."},{"issue":"5","key":"2020061504534200800_CIT0028","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1007\/s40263-016-0337-4","article-title":"Treatment options for narcolepsy","volume":"30","author":"Barateau","year":"2016","journal-title":"CNS Drugs."},{"key":"2020061504534200800_CIT0029","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.sleep.2014.10.002","article-title":"Clinical and practical considerations in the pharmacologic management of narcolepsy","volume":"16","author":"Thorpy","year":"2015","journal-title":"Sleep Med"}],"container-title":["Sleep"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/sleep\/advance-article-pdf\/doi\/10.1093\/sleep\/zsaa009\/32740181\/zsaa009.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/43\/6\/zsaa009\/33373286\/zsaa009.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/sleep\/article-pdf\/43\/6\/zsaa009\/33373286\/zsaa009.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T08:56:31Z","timestamp":1592211391000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/sleep\/article\/doi\/10.1093\/sleep\/zsaa009\/5717181"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1,29]]},"references-count":29,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2020,1,29]]},"published-print":{"date-parts":[[2020,6,15]]}},"URL":"https:\/\/doi.org\/10.1093\/sleep\/zsaa009","relation":{},"ISSN":["0161-8105","1550-9109"],"issn-type":[{"value":"0161-8105","type":"print"},{"value":"1550-9109","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,6]]},"published":{"date-parts":[[2020,1,29]]},"article-number":"zsaa009"}}